Trethera Corporation, a biopharmaceutical company focused on developing groundbreaking treatments for cancer and autoimmune disorders, has announced a significant advancement in its intellectual property portfolio. The company has secured an exclusive, worldwide licensing agreement with the University of California, Los Angeles (UCLA), to enhance its patent estate for TRE-515. This lead compound, a deoxycytidine kinase (dCK) inhibitor, is poised to address new therapeutic applications in autoimmune and inflammatory diseases, alongside its existing cancer treatment potential. The newly acquired license encompasses both method of use claims and compound structures, substantially enlarging Trethera’s patent protection in major pharmaceutical markets worldwide. This strategic acquisition, when combined with Trethera’s current patents and filings, promises market exclusivity for TRE-515 until February 2045. This aligns with Trethera's long-term commercial objectives, ensuring a robust market presence and sustained growth. Dr. Ken Schultz, Chairman and CEO of Trethera, emphasized the importance of this intellectual property expansion, stating that it strengthens their already solid patent base. He highlighted how their composition of matter patent and continuous proprietary discovery efforts form a comprehensive patent strategy. This strategy aims to safeguard the clinical and commercial potential of TRE-515 across numerous therapeutic domains. TRE-515 is currently undergoing Phase 1 clinical trials for cancer treatment and has an expanded access program for ALS (amyotrophic lateral sclerosis, often referred to as Lou Gehrig’s disease). Additionally, promising preclinical research is being conducted for autoimmune and inflammatory diseases. Trethera’s growing intellectual property portfolio boasts multiple granted U.S. and international patents, along with pending applications that cover both composition and method of use claims across oncology and immunology. Amir Naiberg, Associate Vice Chancellor and CEO & President of UCLA’s Technology Development Group, expressed excitement about partnering with Trethera. He acknowledged Trethera’s deep expertise in product development and UCLA’s innovative research capabilities as crucial components in creating commercially viable treatments for significant unmet healthcare needs. Furthermore, UCLA professor Dr. Peter M. Clark, who invented the licensed patent, recognized the agreement as a pivotal step toward commercial approval of dCK inhibitors. He noted that the patent claims include novel chemical structures and applications in immune-mediated disorders. Trethera's leadership is instrumental in translating these scientific discoveries into practical therapeutic solutions. Trethera has already received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a composition of matter patent covering TRE-515, effective until November 2041. This provides Trethera with a formidable patent runway. The company is actively pursuing global patent efforts, with filings in major markets such as Europe, China, and Japan. With the newly licensed patent and a burgeoning international IP portfolio, Trethera is well-positioned as it moves forward with regulatory approval and commercialization of TRE-515. Trethera, a privately held, clinical-stage biopharmaceutical company, is dedicated to pioneering novel treatments for autoimmune diseases and cancers. Founded by renowned UCLA scientists, Trethera is guided by experienced management and board members. Their innovative strategy focuses on targeting nucleotide metabolism, leading to the development of TRE-515. This orally administered capsule has twice received Orphan Drug designation from the FDA. TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), a key enzyme in the nucleoside salvage pathway, which generates DNA precursors. Some cancer forms may rely heavily on this pathway to support tumor growth, and certain autoimmune diseases might also respond favorably to TRE-515 treatment. Trethera is advancing TRE-515 for use as a standalone treatment or in combination therapies, aiming to precisely target metabolic vulnerabilities in cancer and autoimmune diseases to transform patient outcomes.